Clinical and biologic implications of recurrent genomic aberrations in myeloma

Thumbnail
View/Open
Issue date
2003
Author
Fonseca, Rafael
Blood, Emily
Rué i Monné, Montserrat
Harrington, David
Oken, Martin M.
Kyle, Robert A.
Dewald, Gordon W.
Van Ness, Brian
Van Wier, Scott A.
Henderson, Kimberly J.
Bailey, Richard J.
Greipp, Philip R.
Suggested citation
Fonseca, Rafael; Blood, Emily; Rué i Monné, Montserrat; Harrington, David; Oken, Martin M.; Kyle, Robert A.; ... Greipp, Philip R.. (2003) . Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood, 2003, vol. 101, núm. 11, p. 4569-4575. https://doi.org/10.1182/blood-2002-10-3017.
Impact

Google Scholar logo  Google Scholar
Share
Export to Mendeley
Metadata
Show full item record
Abstract
Nonrandom recurrent chromosomal abnormalities are ubiquitous in multiple myeloma (MM) and include, among others, translocations of the immunoglobulin heavy chain locus (IgH). IgH translocations in MM result in the up-regulation of oncogenes, and include more commonly t(11;14)(q13;q32), t(4;14)(p16;q32), and t(14;16)(q32;q23). Based on the recurrent nature of these translocations and their finding since the early stages of the plasma cell (PC) disorders, we hypothesized that they would confer biologic and clinical variability. In addition, deletions of 13q14 and 17p13 have also been associated with a shortened survival. We used cytoplasmic Ig–enhanced interphase fluorescent in situ hybridization to detect deletions (13q14 and 17p13.1), and translocations involving IgH in 351 patients treated with conventional chemotherapy entered into the Eastern Cooperative Oncology Group clinical trial E9486/9487. Translocations were frequently unbalanced with loss of one of the derivative chromosomes. The presence of t(4; 14)(p16;q32) (n 42; 26 vs 45 months, P < .001), t(14;16)(q32;q23) (n 15; 16 vs 41 months, P .003), 17p13 (n 37; 23 vs 44 months, P .005), and 13q14 (n 176; 35 vs 51 months, P .028) were associated with shorter survival. A strati- fication of patients into 3 distinct categories allowed for prognostication: poor prognosis group (t(4;14)(p16;q32), t(14; 16)(q32;q23), and 17p13), intermediate prognosis ( 13q14), and good prognosis group (all others), with median survivals of 24.7, 42.3, and 50.5 months, respectively (P < .001). This molecular cytogenetic classification identifies patients into poor, intermediate, and good risk categories. More importantly it provides further compelling evidence that MM is composed of subgroups of patients categorized according to their underlying genomic aberrations.
URI
http://hdl.handle.net/10459.1/57039
DOI
https://doi.org/10.1182/blood-2002-10-3017
Is part of
Blood, 2003, vol. 101, núm. 11, p. 4569-4575
Collections